Recardio

Regenerative Cardiac Medicine of Tomorrow

  • Company
    • Profile
    • Management Board
    • Boards
    • Awards
  • Pipeline
    • Background
    • Rationale
    • Therapy
  • Clinical Studies
    • Phase 1
    • Phase 2B AMI
    • Phase 2B CHF
  • News & Events
    • Meet us at
  • Careers

Phase 2B CHF

Phase 2B Study in CHF (REC-DUT-003)

The planned global multicenter, randomized, double blind, placebo controlled, parallel group study will evaluate the benefit of dutogliptin in combination with G-CSF as an adjunct treatment for patients with chronic heart failure.

Status of Study

Planned to start in 2019.

Study Design

The double-blind, randomized, placebo-controlled study (Phase 2B) will evaluate both safety and efficacy of dutogliptin in combination with G-CSF as an adjunct treatment for patients with chronic heart failure.

  • Contact us
  • Imprint
  • Data Privacy

© Recardio inc. 2019 · All Rights Reserved

Copyright © 2019 · Altitude Pro Theme on Genesis Framework · WordPress · Log in